Who should these medications be prescribed for?
These medications are used to treat type 2 diabetes and obesity.
Type 2 diabetes: They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. They may be used alone or in combination with other diabetes medications.
Obesity: They are used as an adjunct to a reduced-calorie diet and increased physical activity to help promote weight loss in adults with a body mass index (BMI) of 30 or higher, or in adults with a BMI of 27 or higher who have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol.
Semaglutide is not recommended for use in patients with type 1 diabetes or diabetic ketoacidosis. It is also not recommended for use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as semaglutide may increase the risk of these conditions.
As with any medication, they should only be prescribed by a healthcare provider who has evaluated the patient’s medical history, current health status, and individual needs and goals. Patients should follow their healthcare provider’s instructions for use and attend regular follow-up appointments to monitor progress and assess the need for continued treatment.
Type 2 diabetes: They are used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. They may be used alone or in combination with other diabetes medications.
Obesity: They are used as an adjunct to a reduced-calorie diet and increased physical activity to help promote weight loss in adults with a body mass index (BMI) of 30 or higher, or in adults with a BMI of 27 or higher who have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol.
Semaglutide is not recommended for use in patients with type 1 diabetes or diabetic ketoacidosis. It is also not recommended for use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as semaglutide may increase the risk of these conditions.
As with any medication, they should only be prescribed by a healthcare provider who has evaluated the patient’s medical history, current health status, and individual needs and goals. Patients should follow their healthcare provider’s instructions for use and attend regular follow-up appointments to monitor progress and assess the need for continued treatment.
Updated on: 01/05/2024
Thank you!